ERNA

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced significant progress in the development of ERNA-101, the company's lead therapeutic candidate, achieving multiple critical milestones that position the program for a planned Investigational New Drug (IND) submission in the third quarter of 2026 and the anticipated initiation of its first-in-human clinical study. The company has successfully completed process development activities for the ERNA-101 manufacturing process and has now transitioned into Good Manufacturing Practice

Discussion highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Segment also discusses evolving treatment landscape, immunologically "cold" tumors and the future potential of off-the-shelf cell therapy approaches Access the segment here CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yal

SCHEDULE 13G/A - Ernexa Therapeutics Inc. (0000748592) (Subject)

DEFA14A - Ernexa Therapeutics Inc. (0000748592) (Filer)

DEF 14A - Ernexa Therapeutics Inc. (0000748592) (Filer)

10-Q - Ernexa Therapeutics Inc. (0000748592) (Filer)

Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape  Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies Access the segment here Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce Register for the Closing Bell event here  CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Inves

CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 blockade, drives complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models. "This data represents a significant step forward," said Robert H. Pierce, M.D., Chief Scientific Officer of Ernexa Therapeutics. "We are not just seeing strong response, we are seeing complete tumor eradication and durable survival, driven by a powerful immune activ

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the "Common Stock"), at a ratio of 1-for-25, effective May 4, 2026 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on May 4, 2026, under the existing trading symbol "ERNA." The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continu

DEF 14C - Ernexa Therapeutics Inc. (0000748592) (Filer)

PRE 14C - Ernexa Therapeutics Inc. (0000748592) (Filer)

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in-human study planned for Q4 2026 for the treatment of platinum-resistant ovarian cancer Multiple regulatory and clinical milestones expected to drive significant value creation over the next 12-18 months CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today provided a business update highlighting the Company's accelerating t

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-3/A - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

10-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026, at 4:00 PM ET. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, will provide a corporate overview and business outlook. In addition to the moderated discussion

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

424B5 - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (NASDAQ:ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $0.68 per share, will be exercisable upon issuance, and will e

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

CERT - Ernexa Therapeutics Inc. (0000748592) (Filer)